AMAL Therapeutics to publish R&D outcomes in Cancers

Geneva, Switzerland, February 17, 2021 – AMAL Therapeutics announced today that its recent research findings, in collaboration with Fox Chase Cancer Center, about a novel protein‐based vaccine against self‐antigen reducing the formation of sporadic colon adenomas in mice, is on line on the Cancers website. The publication demonstrate Ascl2 as a promising target for immunoprevention for individuals at elevated risk of developing colorectal cancer.